| Business Summary | | ICOS
Corporation
is
a
product-driven
company
that
has
expertise
in
both
protein-based
and
small
molecule
therapeutics.
The
Company
combines
its
capabilities
in
molecular,
cellular
and
structural
biology,
high-throughput
drug
screening,
medicinal
chemistry
and
genomics
to
develop
products
with
commercial
potential.
The
Company
is
evaluating
Cialis,
a
small
molecule
compound
that
inhibits
the
phosphodiesterase
type
five
enzyme
for
the
treatment
of
male
erectile
dysfunction
and
female
sexual
dysfunction.
The
Company
is
also
evaluating
Pafase,
a
recombinant
human
serum
protein,
for
the
treatment
of
sepsis
and
other
diseases
characterized
by
increased
activity
of
platelet-activating
factor. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ICOS
is
discovering
and
developing
new
pharmaceuticals
by
seeking
points
of
intervention
in
disease
processes
that
may
lead
to
more
specific
and
efficacious
drugs.
For
the
six
months
ended
6/30/01,
revenues
rose
44%
to
$52.9
million.
Net
loss
before
accounting
change
rose
61%
to
$20.4
million.
Revenues
reflect
the
inclusion
of
a
$15
million
license
fee
from
Lilly
ICOS.
Net
loss
reflects
an
increase
in
equity
in
losses
of
affiliates. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Paul Clark, 54 Chairman,
Pres, CEO | $878K | -- | Michael Stein, 51 CFO,
VP | -- | -- | Gary Wilcox, Ph.D., 54 Exec.
VP of Operations, Sec. | 416K | $112K | Leonard Blum, 40 VP
of Sales and Marketing | -- | -- | W. Gallatin, Ph.D., 47 VP
and Scientific Director | 308K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|